Results 41 to 50 of about 17,756 (301)

The importance of early diagnosis and treatment of kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon

Dermatology Practical & Conceptual, 2015
Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that may be complicated by Kasabach-Merritt phenomenon (KMP), a profound thrombocytopenia resulting from platelet trapping within a vascular tumor, either KHE or tufted angioma (
Grecia V. Vivas-Colmenares, Gema L. Ramirez-Villar, Jose A. Matute de Cardenas, Jose Bernabeu-Wittel, Israel Fernandez-Pineda   +4 more
doaj   +1 more source

Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis

BMC Neurology, 2021
Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but their relative effectiveness and harms still need to be clarified.
Cinzia Del Giovane, Giorgio B. Boncoraglio, Lorenza Bertù, Rita Banzi, Irene Tramacere   +4 more
doaj   +1 more source

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]

, 2009
<p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Cucchiara, B., Demchuk, A., Kasner, S.E., Lees, K.R., Levine, S.R., Lyden, P., Messe, S.R., Sansing, L., Tanne, D.   +8 more
core   +1 more source

Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study.

Nephrology, Dialysis and Transplantation, 2014
BACKGROUND Patients undergoing kidney transplantation are sometimes being treated with antiplatelet agents such as ticlopidine or clopidogrel. Some teams refuse to wait-list these patients for fear of bleeding during transplant surgery.
A. Benahmed, Mireille N. Kianda, L. Ghisdal, N. Broeders, A. Massart, Anne Lemy, D. Mikhalski, A. Hoang, V. Donckier, C. Sadis, A. Le Moine, P. Madhoun, J. Racapé, M. Wissing, D. Abramowicz   +14 more
semanticscholar   +1 more source

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study [PDF]

, 2016
BACKGROUND & AIMS: We performed a genome-wide association study (GWAS) to identify genetic risk factors for druginduced liver injury (DILI) from licensed drugs without previously reported genetic risk factors.
Aithal, Guruprasad P., Andrade, Raul J., Arrese, Marco, Barnhart, Huiman X., Bessone, Fernando, Bjornsson, Einar S., Bondon-Guitton, Emmanuelle, Carvajal, Alfonso, Cascorbi, Ingolf, Chalasani, Naga, Cirulli, Elizabeth T., Conforti, Anita, Coulthard, Sally A., Daly, Ann K., Daly, Mark J., Day, Christopher P., Dillon, John F., Drug-Induced Liver Injury Network, Floratos, Aris, Fontana, Robert J., Grove, Jane I., Hallberg, Par, Hayashi, Paul H., Hernandez, Nelia, Ibanez, Luisa, Int Drug-Induced Liver Injury Cons, Int Serious Adverse Events Consort, Kullak-Ublick, Gerd A., Laitinen, Tarja, Larrey, Dominique, Lucena, M. Isabel, Maitland-van der Zee, Anke H., Martin, Jennifer H., Molokhia, Mariam, Nelson, Matthew R., Nicoletti, Paola, Pirmohamed, Munir, Powell, Elizabeth E., Qin, Shengying, Sawle, Ashley, Serrano, Jose, Shen, Yufeng, Stephens, Camilla, Stolz, Andrew, Urban, Thomas J., Wadelius, Mia, Watkins, Paul B.   +46 more
core   +10 more sources

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?

Current Controlled Trials in Cardiovascular Medicine, 2000
The cornerstone in clinical evidence of the relative efficacy of thienopyridines (clopidogrel, ticlopidine) versus aspirin in the secondary prevention of vascular disease is the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events trial ...
Algra Ale, van Gijn Jan
doaj   +1 more source

Medical Adjuvant Therapy in Reducing Thrombosis With Arteriovenous Grafts and Fistulae Use: A Meta-Analysis of Randomized Controlled Trials

Clinical and Applied Thrombosis/Hemostasis, 2021
Hemodialysis is required for patients with end-stage renal disease (ESRD) that require arteriovenous (AV) grafts or fistulas for vascular access. These access points are prone to thrombosis. To determine the effect of medical adjuvant therapy on AV graft/
Kaleem Ullah MBBS, Maham Bashir MBBS, Noor Ul Ain MBBS, Azza Sarfraz MBBS, Zouina Sarfraz MBBS, Muzna Sarfraz MBBS, Ivan Cherrez-Ojeda MD, MSc   +6 more
doaj   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies.

Blood, 2013
To the editor: The antiplatelet agent ticlopidine is associated with the rapid onset of a thrombotic microangiopathy (TMA) resembling thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic-uremic syndrome (aHUS). These disorders occur in 0.06%
J. Chapin, S. Eyler, Richard J. H. Smith, H. Tsai, J. Laurence   +4 more
semanticscholar   +1 more source

Emerging Strategies for Platelet‐Modified Nanoparticles in Targeted Tumor Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights innovative strategies using platelet‐modified nanoparticles to target tumors more precisely. By mimicking platelet functions, these biomimetic carriers improve tumor homing, enhance drug delivery, and reduce immune clearance.
Chunyu Bai, Lan Sun, Yimin Cui, Huan Meng, Jiulong Li, Qian Xiang   +5 more
wiley   +1 more source